197 related articles for article (PubMed ID: 25555352)
1. Recent advances in targeted nanoparticles drug delivery to melanoma.
Li J; Wang Y; Liang R; An X; Wang K; Shen G; Tu Y; Zhu J; Tao J
Nanomedicine; 2015 Apr; 11(3):769-94. PubMed ID: 25555352
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma.
Hughes T; Klairmont M; Sharfman WH; Kaufman HL
Cancer Biol Ther; 2021 Dec; 22(10-12):513-526. PubMed ID: 26418961
[TBL] [Abstract][Full Text] [Related]
3. Nanocarrier-Based Drug Delivery for Melanoma Therapeutics.
Song M; Liu C; Chen S; Zhang W
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668591
[TBL] [Abstract][Full Text] [Related]
4. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
[TBL] [Abstract][Full Text] [Related]
5. Targeted drug delivery to melanoma.
Liu Q; Das M; Liu Y; Huang L
Adv Drug Deliv Rev; 2018 Mar; 127():208-221. PubMed ID: 28939379
[TBL] [Abstract][Full Text] [Related]
6. Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
Michielin O; Hoeller C
Cancer Treat Rev; 2015 Sep; 41(8):660-70. PubMed ID: 26096079
[TBL] [Abstract][Full Text] [Related]
7. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
8. [Molecular-target therapy for advanced malignant melanoma].
Takahashi S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):19-25. PubMed ID: 23306915
[TBL] [Abstract][Full Text] [Related]
9. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Melanoma: Recent Advances and Promising New Therapies.
Saraceni MM; Khushalani NI; Jarkowski A
J Pharm Pract; 2015 Apr; 28(2):193-203. PubMed ID: 24674910
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy.
Brys AK; Gowda R; Loriaux DB; Robertson GP; Mosca PJ
Biotechnol Adv; 2016; 34(5):565-577. PubMed ID: 26826558
[TBL] [Abstract][Full Text] [Related]
12. Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review.
Rigon RB; Oyafuso MH; Fujimura AT; Gonçalez ML; do Prado AH; Gremião MP; Chorilli M
Biomed Res Int; 2015; 2015():841817. PubMed ID: 26078967
[TBL] [Abstract][Full Text] [Related]
13. Recent developments in nanomedicine for melanoma treatment.
Tang JQ; Hou XY; Yang CS; Li YX; Xin Y; Guo WW; Wei ZP; Liu YQ; Jiang G
Int J Cancer; 2017 Aug; 141(4):646-653. PubMed ID: 28340496
[TBL] [Abstract][Full Text] [Related]
14. The scope of nanoparticle therapies for future metastatic melanoma treatment.
Bombelli FB; Webster CA; Moncrieff M; Sherwood V
Lancet Oncol; 2014 Jan; 15(1):e22-32. PubMed ID: 24384491
[TBL] [Abstract][Full Text] [Related]
15. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
[TBL] [Abstract][Full Text] [Related]
16. New drugs in melanoma: it's a whole new world.
Eggermont AM; Robert C
Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
[TBL] [Abstract][Full Text] [Related]
17. Anti-PD-1 therapy in melanoma.
Homet Moreno B; Parisi G; Robert L; Ribas A
Semin Oncol; 2015 Jun; 42(3):466-73. PubMed ID: 25965365
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab in previously untreated melanoma without BRAF mutation.
Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
[TBL] [Abstract][Full Text] [Related]
19. The development of site-specific drug delivery nanocarriers based on receptor mediation.
Wang X; Li S; Shi Y; Chuan X; Li J; Zhong T; Zhang H; Dai W; He B; Zhang Q
J Control Release; 2014 Nov; 193():139-53. PubMed ID: 24862317
[TBL] [Abstract][Full Text] [Related]
20. Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma.
Wang H; Tran TT; Duong KT; Nguyen T; Le UM
Mol Pharm; 2022 Dec; 19(12):4487-4505. PubMed ID: 36305753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
